CompanyCALCNasdaqLa Jolla, CA

CalciMedica, Inc.

Clinical-stage biopharmaceutical company developing small-molecule CRAC channel inhibitors for inflammatory and immunologic diseases.

SEC EDGAR ClinicalTrials.gov

8-KSep 30Latest SEC filing

Sep 30Latest story

September 2026

CalciMedica files for up to $25 million at-the-market stock offering

Sep 30FinancingCalciMedica, Inc.

August 2026

CalciMedica stockholders back plan increase, reverse split, and warrant issuances at annual meeting

Aug 19PeopleCalciMedica, Inc.

CalciMedica reports Q2 2026 results, advances pulmonary hypertension and pancreatitis programs

Aug 11Quarterly updateCalciMedica, Inc.

July 2026

CalciMedica appoints Zaytsev to board, expands to eight directors

Jul 7PeopleCalciMedica, Inc.